Cargando…
A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of ther...
Autores principales: | Sjöberg, Folke, Waters, Susanna, Löfberg, Boel, Sonesson, Clas, Waters, Nicholas, Tedroff, Joakim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137807/ https://www.ncbi.nlm.nih.gov/pubmed/34018344 http://dx.doi.org/10.1002/prp2.792 |
Ejemplares similares
-
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
por: Svenningsson, Per, et al.
Publicado: (2018) -
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018) -
Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder
por: Forssberg, Hans, et al.
Publicado: (2006) -
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018) -
Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)